Does xgeva help prevent bone fractures in cancer patients?

Does Xgeva reduce bone fractures in cancer patients?

Xgeva reduces skeletal-related events including fractures in patients with bone metastases from solid tumors. It binds to RANKL and blocks osteoclast activity, reducing bone breakdown and pain.

What types of cancer does Xgeva target?

It treats patients with bone metastases from breast, prostate, and other solid tumors. It also works in multiple myeloma patients who develop bone lesions.

How does Xgeva compare to Zometa?

Xgeva proves superior to Zometa in delaying time to first skeletal-related event and preventing subsequent events. Studies show it reduces fracture risk more effectively than bisphosphonates in many cases.

When does Xgeva patent expire?

The primary composition-of-matter patent for denosumab expires in 2025 in the United States. Biosimilar versions of Xgeva are already entering some markets.